Table 1.

Summary of randomized controlled trials testing the benefit of imatinib in metastatic/unresectable GIST.

Trial	N	Phase	Primary endpoint	Imatinib dose	PFS	OS
B2222	147	II	Response	400 mg qd 600 mg qd	24 months median	57 months median
EORTC 62005	946	III	PFS	400 mg qd 400 mg bid	22 months median† 27 months median†*	69% at 2 yrs 74% at 2 yrs
SWOG S0033	746	III	PFS/OS	400 mg qd 400 mg bid	18 months median 20 months median	55 months median 51 months median

EORTC – European Organization for Research and Treatment of Cancer; SWOG – Southwest Oncology Group; PFS – progression-free survival; OS – overall survival. Based on references 13–16.

^†estimate as actual number not stated in manuscript;

^*p<0.05